'Interim Budget has ignited the entrepreneurial spirit.'
'However, we have seen weakness in our active pharmaceutical ingredients business.'
Sources indicated that there were no fresh orders from the Government of India, and their supply commitments have ended as of March 31, reports Sohini Das.
Balkrishna V Doshi, who won the Pritzker Award in 2018 -- which is equivalent to the Nobel Prize in architecture -- passed into the ages this week. Sohini Das recalls an encounter with the the legendary architect, who was posthumously awarded the Padma Vibhushan in this year's Republic Day honours list.
'The US has invoked the Defence Act and banned export of raw materials.' 'This is as good as banning vaccines.'
'And a majority will be in the top-end vehicle range.'
This will be an upfront payment for the vaccine doses that these two companies will supply to the government.
The company had in December said that the CDSCO had approved a 12-month shelf life for Covaxin, which was nine months earlier, Sohini Das reports.
With just a month left in this financial year, electric two-wheeler sales, so far, are at just 62 per cent of the ambitious target of 1 million units set for 2022-23 by the NITI Aayog. According to VAHAN data, compiled by the Society of Manufacturers of Electric Vehicles (SMEV), 620,006 units of electric two-wheelers were sold across the country in FY23 until February 21. Though the industry may miss the 1-million target, sales in FY23 are already up 146 per cent from 249,621 units sold in FY22.
The production of Covaxin will increase from the current 10 million doses per month to 60 million-70 million by July-August.
With around 2 million Covid vaccine doses likely to get wasted in December, leading hospital chains have now started to give it gratis to citizens. Sohini Das and Ruchika Chitravanshi report.
ICMR's serological survey, whose findings will be made public next week, suggests that the rate of contagion may be a lot higher in most-affected cities such as Delhi, Mumbai, and Pune.
Sources close to the development said the company had no further supply commitments to the WHO, and therefore, there was no suspension of any upcoming orders, reports Sohini Das.
With intermittent disruptions in the supply chain of raw materials from China, the Indian pharma industry has braced itself with bigger inventory. Even smaller drug makers are now carrying a month of buffer stock of key raw materials, said industry insiders. The lockdown in various Chinese provinces, including Shanghai, is likely to delay shipments by two weeks to a month, said domestic players. Shipments are critical for the Indian drug industry, which imports 70 per cent of its raw material from China.
The Centre is looking to procure around 1 billion syringes between September and December to support the COVID-19 vaccination drive.
Apollo Hospitals and Fortis Healthcare are open to importing vaccines.
Drugs that are used to treat Covid or used by people as immunity boosters have seen a jump in sales and, in turn, rankings.
The primary objective was to get the adult vaccine as children rarely have a severe form of the disease. Once schools reopen, the demand for vaccines for children under 12 may soar.
Indian companies are planning to increase investments in the new year to expand capacity, acquire companies, and go on a hiring spree, a survey of top executives showed. They, however, cited rising costs, weak consumer demand, and increasing interest rates as major concerns for 2023 which may impact their plans.
SII would be scaling up its AstraZeneca-Oxford vaccine manufacturing capacity to 200 million doses a month from 100 million a month now, reports Sohini Das.
The government may look at areas around Thonnakkal, in Thiruvananthapuram district, for the facility. If successful, this would be one of the few sites of Sputnik V owned by Russian firms outside that country. Shine Jacob and Sohini Das report.
However, Cipla was very clear it does not want to get into vaccine manufacturing.
Serum Institute already has two deals of 100 million each to supply the Oxford-AstraZeneca and the Novavax vaccine to Gavi-Covax at $3 per dose.
Government institutions and pharma industry are examining if a 'cocktail' approach to making a multi-variant Covid-19 vaccine works against multiple strains of the ever-mutating virus, reports Sohini Das.
'The tie-up with Serum Institute Life Sciences brings to the table their strengths in manufacturing and also their vaccine portfolio.'
The telecast was viewed by 197 million Indians, higher than the Indian Premier League final which was watched by 133 million, reports Sohini Das.
'The Centre is planning to procure five million vials of Remdesivir ahead of the third wave. What's better is that this time, the government is paying us in advance,' said a senior executive of a Mumbai-based pharma player which makes Remdesivir. Sohini Das reports.
A longer shelf life is critical, given many makers have started manufacturing vaccines and stockpiling them, so as to make them available in the market immediately after approval, reports Sohini Das.
By January-February, it's expected to have at least 100 million doses for the Indian government, reports Sohini Das.
'The key purpose of vaccination is to prevent hospitalisation, severe disease, and death.' 'All vaccines work equally, although mild disease cannot be prevented.'
The Covid-19 vaccine demonstrated an overall 90.4 per cent efficacy in phase 3 clinical trials, reports Sohini Das
This could also be India's first vaccine for children aged 12 years and above as the company has conducted trials on the age group. The decision, however, lies with the regulator, reports Sohini Das
The company has developed detailed logistical plans and tools to support effective vaccine transport, storage, and temperature monitoring. Sohini Das and Ruchika Chitravanshi report.
Providence will sell up to 30 mn doses of its mRNA vaccine to Biological E. It would also provide the necessary technology transfer to make the vaccine in India, with a minimum production capacity of 600 mn doses in 2022 and targets capacity of 1 bn doses, reports Sohini Das.
500 million doses per annum from its two sites in Hyderabad and 200 million doses each from its Ankleshwar and Kolar facilities.
Artificial shortages and brazen hawking of the drug on the streets at 15 times the normal price rule the day as the official machinery tries desperately to stamp out the parallel market, reports Sohini Das
While the Indian government has been procuring Covid-19 vaccines at low prices so far, manufacturers have to declare the prices of vaccines they would supply to the open market (industries, private hospitals, etc) and state governments before May 1. Sohini Das reports.
The global trials were halted after a study participant suffered a 'potentially unexplained illness, reports Sohini Das.
Experts, however, feel that given the intensity of the second wave and the high single dose coverage, India is in a good position to avoid any drastic wave in the near future.
The company raised $145 million (about Rs 1,000 crore) recently from investors. The portal, which has 15 million unique customers and 32 million visits per month, is already a market leader. Sohini Das reports from Ahmedabad.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances